Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization.
TRPV1 agonist
atomic force microscopy (AFM)
capsaicin
in vitro release
lipid nanocarrier (LN)
spontaneous pain
western blot analysis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
10 Apr 2020
10 Apr 2020
Historique:
received:
09
03
2020
revised:
07
04
2020
accepted:
08
04
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
4
2020
Statut:
epublish
Résumé
Capsaicin (CPS) is a highly selective agonist of the transient receptor potential vanilloid type 1 (TRPV1) with a nanomolar affinity. High doses or prolonged exposure to CPS induces TRPV1 defunctionalization and, although this effect is currently used for the treatment of thermal hyperalgesia in chronic pain conditions, it is responsible of detrimental effects, such as denervation of sensory fibers. The aim of the present study was to formulate CPS loaded lipid nanocarriers (CPS-LN) in order to optimize CPS release, thus preventing TRPV1 internalization and degradation. CPS-LNs were formulated and characterized by in vitro studies. The activation of TRPV1 receptors after CPS-LN administration was evaluated by measuring spontaneous pain that was induced by local injection into the plantar surface of the mouse hind-paw. Moreover, the expression of TRPV1 in the skin was evaluated by western blot analysis in CPS-LN injected mice and then compared to a standard CPS solution (CPS-STD). CPS inclusion in LN induced a lower pain response when compared to CPS-STD; further, it prevented TRPV1 down-regulation in the skin, while CPS-STD induced a significant reduction of TRPV1 expression. Drug encapsulation in lipid nanoparticles produced an optimization of CPS release, thus reducing mice pain behavior and avoiding the effects that are caused by TRPV1 defunctionalization related to a prolonged activation of this receptor.
Sections du résumé
BACKGROUND
BACKGROUND
Capsaicin (CPS) is a highly selective agonist of the transient receptor potential vanilloid type 1 (TRPV1) with a nanomolar affinity. High doses or prolonged exposure to CPS induces TRPV1 defunctionalization and, although this effect is currently used for the treatment of thermal hyperalgesia in chronic pain conditions, it is responsible of detrimental effects, such as denervation of sensory fibers. The aim of the present study was to formulate CPS loaded lipid nanocarriers (CPS-LN) in order to optimize CPS release, thus preventing TRPV1 internalization and degradation.
METHODS
METHODS
CPS-LNs were formulated and characterized by in vitro studies. The activation of TRPV1 receptors after CPS-LN administration was evaluated by measuring spontaneous pain that was induced by local injection into the plantar surface of the mouse hind-paw. Moreover, the expression of TRPV1 in the skin was evaluated by western blot analysis in CPS-LN injected mice and then compared to a standard CPS solution (CPS-STD).
RESULTS
RESULTS
CPS inclusion in LN induced a lower pain response when compared to CPS-STD; further, it prevented TRPV1 down-regulation in the skin, while CPS-STD induced a significant reduction of TRPV1 expression.
CONCLUSIONS
CONCLUSIONS
Drug encapsulation in lipid nanoparticles produced an optimization of CPS release, thus reducing mice pain behavior and avoiding the effects that are caused by TRPV1 defunctionalization related to a prolonged activation of this receptor.
Identifiants
pubmed: 32290081
pii: pharmaceutics12040339
doi: 10.3390/pharmaceutics12040339
pmc: PMC7238012
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Pain. 2010 Jun;11(6):588-99
pubmed: 20015699
J Biol Chem. 2001 Jul 27;276(30):28613-9
pubmed: 11358970
J Agric Food Chem. 2007 Jul 25;55(15):5925-33
pubmed: 17608494
Int J Pharm. 2009 Jan 21;366(1-2):170-84
pubmed: 18992314
Eur Urol. 2005 Oct;48(4):691-8
pubmed: 15992990
Med Hypotheses. 2009 Jul;73(1):100-2
pubmed: 19328632
Biochim Biophys Acta. 2007 Aug;1772(8):937-46
pubmed: 17616360
Eur J Pharm Sci. 2005 May;25(1):81-9
pubmed: 15854804
Pharmacol Rev. 2012 Oct;64(4):939-71
pubmed: 23023032
AAPS PharmSciTech. 2003;4(1):E7
pubmed: 12916916
Int J Pharm. 2013 Oct 15;455(1-2):348-56
pubmed: 23850626
Arch Dermatol Res. 1997 Sep;289(10):578-84
pubmed: 9373717
Protein Cell. 2017 Mar;8(3):169-177
pubmed: 28044278
Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R64-76
pubmed: 16973931
Eur J Pharm Biopharm. 2003 Jan;55(1):125-31
pubmed: 12551713
J Neurosci. 1998 Nov 1;18(21):8947-59
pubmed: 9787000
Cancer Res. 2009 Feb 1;69(3):905-13
pubmed: 19155296
Sci Signal. 2019 Apr 02;12(575):
pubmed: 30940767
Eur J Biochem. 2004 May;271(10):1820-6
pubmed: 15128292
Eur J Pharm Biopharm. 2011 Sep;79(1):189-96
pubmed: 21352915
Nat Rev Neurosci. 2001 Jun;2(6):387-96
pubmed: 11389472
Carcinogenesis. 2011 May;32(5):779-85
pubmed: 21349818
Br J Pharmacol. 2008 Dec;155(8):1145-62
pubmed: 18806809
Eur J Med Chem. 2019 Nov 15;182:111634
pubmed: 31472474
J Clin Oncol. 1997 Aug;15(8):2974-80
pubmed: 9256142
Eur J Pharm Biopharm. 2007 Sep;67(2):320-8
pubmed: 17368876
Brain Res. 1987 Aug 18;418(1):201-3
pubmed: 3664271
Int J Pharm. 2008 Jun 5;357(1-2):295-304
pubmed: 18343059
Br J Anaesth. 2011 Oct;107(4):490-502
pubmed: 21852280
Mater Sci Eng C Mater Biol Appl. 2013 Dec 1;33(8):4923-34
pubmed: 24094206
Expert Opin Drug Deliv. 2012 Apr;9(4):429-41
pubmed: 22394125
Science. 2000 Apr 14;288(5464):306-13
pubmed: 10764638
Mol Pain. 2011 Nov 23;7:90
pubmed: 22112588
J Neurochem. 2007 Aug;102(3):977-90
pubmed: 17442041
Pain. 1988 Jun;33(3):333-40
pubmed: 2458561
J Neurosci. 1999 Mar 1;19(5):1844-54
pubmed: 10024368